Article Text

Download PDFPDF
IL23R and IL12B genes: susceptibility analysis in rheumatoid arthritis
  1. J Varade1,
  2. J Ramón Lamas2,
  3. L Rodríguez2,
  4. M Fernández-Arquero1,
  5. E Loza-Santamaría2,
  6. J Á Jover2,
  7. E G de la Concha1,
  8. B Fernández-Gutierrez2,
  9. E Urcelay1,
  10. A Martínez1
  1. 1
    Immunology Department, Hospital Clínico San Carlos, Madrid, Spain
  2. 2
    Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
  1. Dr J Varadé, Immunology Department, Hospital Universitario Clínico San Carlos, Prof Martin Lagos s/n, 28040 Madrid, Spain; gezabelvarade{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The identification of additional genetic risk factors is an ongoing process that will aid in the understanding of rheumatoid arthritis (RA) aetiology. A genome-wide association scan in Crohn’s disease highlighted the IL23R gene as a susceptibility factor.1 The IL-23 receptor is a heterodimer formed by the products of two different genes: IL23R and IL12RB. Our aim was to analyse whether polymorphisms within the genes coding for the specific chain of the IL-23 receptor (IL23R) and for its p40 ligand (IL12B) and interacting in psoriasis2 are also associated with an altered risk of RA.

In agreement with previously published data,36 no statistically significant association was found with the IL12B polymorphisms (table 1).

View this table:
Table 1 Association of IL23R (rs7517847 and rs11209026) and IL12B (rs6887695 and rs322227) SNP with RA

The minor alleles of the IL23R polymorphisms were associated with increased predisposition to …

View Full Text


  • Funding: This work was supported by Fundación Mutua Madrileña.

  • Competing interests: Declared. AM and JV are employers with support from the Fondo de Investigaciones Sanitarias (04/CP00175) and (CA08/00194). EU works for the Fundación para la Investigación Biomédica-Hospital Clínico San Carlos.

  • Ethics approval: The ethics committee from Hospital Clínico San Carlos approved the study.